Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 5/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | GRM8 | O00222 | 2/20 | 0.31 |
| ▸ | GRM6 | O15303 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24868025 | 0.77 | KDM4E (0.36) | CYP2C19ALDH1A1KDM4E | |
| SCHEMBL9617196 | 0.69 | APLNR (0.42) | CYP2C19APLNRLMNABLMRAB9A | |
| SCHEMBL11246132 | 0.68 | APLNR (0.36) | APLNRFFAR3 | |
| SCHEMBL26938889 | 0.67 | — | — | |
| SCHEMBL4888774 | 0.62 | APLNR (0.41) | CYP2C19APLNRLMNABLMRAB9A | |
| SCHEMBL3696609 | 0.62 | ALDH1A1 (0.36) | CYP2C19ALOX15TSHRTDP1ALDH1A1 | |
| SCHEMBL221717 | 0.62 | APLNR (0.41) | CYP2C19APLNRLMNABLMRAB9A | |
| Methane SCHEMBL3337389 | 0.60 | APLNR (0.39) | CYP2C19APLNRFFAR3 | |
| Hydrochloric Acid SCHEMBL8617904 | 0.60 | APLNR (0.39) | CYP2C19APLNRFFAR3 | |
| Bicarbonate SCHEMBL139212 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634159-A1 | SULFOXIMINES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12122788-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | GRUENENTHAL GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| WO-2024126648-A1 | SULFOXIMINES AS INHIBITORS OF NaV1.8 | Grünenthal GmbH (DE) | 2024-06-20 | — | — | WO | disclosed |
| EP-4013741-B1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMA (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11584761-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584761-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4013741-A1 | PROCESS OF MAKING CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555556-A | Methods of making CFTR modulators | 弗特克斯药品有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
| EP-3752510-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | Vertex Pharmaceuticals Incorporated (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019161078-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20180162839-A1 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | CYP2C19 966/4885APLNR 4520/4885CYP1A2 2282/4885 |
| US-11584761-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | CYP2C19 966/4885APLNR 4520/4885CYP1A2 2282/4885 |
| US-20180162839-A1 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | CFTR, SLC26A4, TMEM109 | CYP2C19 1564/4885APLNR 1544/4885CYP1A2 2126/4885 |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | CYP2C19 501/4885APLNR 2913/4885CYP1A2 1223/4885 |
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | SCN8A, SCN10A, SCN7A | CYP2C19 1908/4885APLNR 1164/4885CYP1A2 1391/4885 |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | CYP2C19 966/4885APLNR 4520/4885CYP1A2 2282/4885 |
| US-12122788-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | CYP2C19 966/4885APLNR 4520/4885CYP1A2 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.